Bionano Genomics, Inc. (BNGO) Insider Trading Activity

NASDAQ$1.1
Market Cap
$12.95M
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
356 of 843
Rank in Industry
22 of 42

BNGO Insider Trading Activity

BNGO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$9,705
2
100
Sells
$0
0
0

Related Transactions

Luderer AlbertInterim Chief Executive
2
$9,705
0
$0
$9,705

About Bionano Genomics, Inc.

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

Insider Activity of Bionano Genomics, Inc.

Over the last 12 months, insiders at Bionano Genomics, Inc. have bought $9,705 and sold $0 worth of Bionano Genomics, Inc. stock.

On average, over the past 5 years, insiders at Bionano Genomics, Inc. have bought $46,265 and sold $72,402 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Luderer Albert (Interim Chief Executive) — $9,705.

The last purchase of 4,000 shares for transaction amount of $4,845 was made by Luderer Albert (Interim Chief Executive) on 2026‑09‑04.

List of Insider Buy and Sell Transactions, Bionano Genomics, Inc.

2026-09-04PurchaseLuderer AlbertInterim Chief Executive
4,000
0.035%
$1.21
$4,845
+10.83%
2026-08-21PurchaseLuderer AlbertInterim Chief Executive
4,000
0.0353%
$1.22
$4,860
+4.17%
2023-06-13PurchaseMamuszka Hannahdirector
65,789
0.0219%
$0.76
$50,000
-80.85%
2023-05-16PurchaseHolmlin R. ErikPresident and CEO
15,000
0.0049%
$0.64
$9,639
-75.22%
2023-05-12PurchaseStewart Christopher P.Chief Financial Officer
50,000
0.0167%
$0.67
$33,415
-75.25%
2022-08-15SaleLinney Yvonne
20,000
0.0069%
$3.62
$72,402
-59.44%
2022-05-16PurchaseBARKER DAVID L
10,000
0.0036%
$1.60
$16,000
+9.55%
2021-11-29PurchaseHolmlin R. ErikPresident and CEO
5,025
0.0018%
$3.99
$20,037
-45.55%
2018-08-23PurchaseDomain Partners VIII, L.P.10 percent owner
30,000
0.372%
$6.13
$183,750
-31.63%
2018-08-23PurchaseTWOMEY CHRISTOPHER Jdirector
20,000
0.248%
$6.13
$122,500
-31.63%
2018-08-23PurchaseHolmlin R. ErikPresident and CEO
3,260
0.0404%
$6.13
$19,968
-31.63%
2018-08-23PurchaseBorodkin MarkChief Operating Officer
1,630
0.0202%
$6.13
$9,984
-31.63%
2018-08-21PurchaseBARKER DAVID Ldirector
7,788
0.1053%
$6.47
$50,388
-29.27%
Total: 13
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Luderer AlbertInterim Chief Executive
8000
0.0679%
$8,800.0020
Domain Partners VIII, L.P.10 percent owner
943878
8.0146%
$1.04M10
Holmlin R. ErikPresident and CEO
806474
6.8479%
$887,121.4030
<0.0001%
Stewart Christopher P.Chief Financial Officer
281373
2.3892%
$309,510.3010
<0.0001%
Mamuszka Hannahdirector
65789
0.5586%
$72,367.9010
<0.0001%
BARKER DAVID L
13894
0.118%
$15,283.4020
+9.55%
TWOMEY CHRISTOPHER Jdirector
10000
0.0849%
$11,000.0010
Borodkin MarkChief Operating Officer
815
0.0069%
$896.5010
Linney Yvonne
0
0%
$001
*Gray background shows insiders who have made transactions during last year

BNGO Institutional Investors: Active Positions

Increased Positions14+33.33%746,348+305.35%
Decreased Positions16-38.1%105,602-43.21%
New Positions9New650,415New
Sold Out Positions8Sold Out46,606Sold Out
Total Postitions40-4.76%885,166+262.15%

BNGO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ubs Group Ag$102.000.64%63,876+61,206+2,292.36%2025-09-30
Vanguard Group Inc$80.000.51%50,459+50,459New2025-09-30
Geode Capital Management, Llc$43.000.27%26,838+7,967+42.22%2025-09-30
Carret Asset Management, Llc$40.000.25%25,000+25,000New2025-09-30
Hrt Financial Lp$32.000.2%20,330+20,330New2025-09-30
Two Sigma Securities, Llc$25.000.16%15,584+15,584New2025-09-30
Stifel Financial Corp$17.000.11%10,513+10,513New2025-09-30
Blackrock, Inc.$16.000.1%9,937+<1+<0.01%2025-09-30
Bank Of America Corp /De/$14.000.09%8,507+98+1.17%2025-09-30
Morgan Stanley$10.000.06%6,208-5,447-46.73%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.